Episodes

  • Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

    Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
    Jun 28 2024
    This PER On Air - Ophthalmology Times podcast examines the new treatment paradigm for patients with geographic atropy, following the introduction of complement-targeting therapies. In this podcast, experts, Dr Cecelia Koetting and Dr Talia Kaden review some of the key highlights from the live satellite symposium, Community Practice Connection™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention presented at the 2024 EnVision Summit in Ophthalmology.
    Show more Show less
    17 mins
  • Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

    Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
    Jun 27 2024
    In this PER On Air Ophthalmology Times podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK.
    Show more Show less
    12 mins
  • Novel Therapies for Neovascular Retinal Disease - Expert Analysis of New Key Data

    Novel Therapies for Neovascular Retinal Disease - Expert Analysis of New Key Data
    Jun 27 2024
    In this PER On Air Ophthalmology Times Podcast, a panel of experts takes a closer look at newer-generation anti-VEGF agents for the treatment of nAMD and DME, sharing insights into clinical trial and real-world data, patient education, and other important considerations for treatment. Faculty: Roger A. Goldberg, MD, MBA Vitreoretinal Specialist Bay Area Retina Associates Volunteer Faculty California Pacific Medical Center Walnut Creek, CA David R.P. Almeida, MD, PhD, MBA President and CEO Erie Retina Research Center for Advanced Surgical Exploration Erie, PA Jennifer I. Lim, MD, FARVO Marion H. Schenk Esq. Chair in Ophthalmology for Research of the Aging Eye UIC Distinguished Professor of Ophthalmology Director, Retina Service Vice-Chair, Diversity and Inclusion University of Illinois at Chicago Chicago, IL
    Show more Show less
    16 mins
  • A stem cell patch for treating advanced dry AMD

    A stem cell patch for treating advanced dry AMD
    Jun 26 2024
    In this Ophthalmology Times EyePod podcast, Mandeep S. Singh, MD, PhD, speaks with Mark S. Humayun, MD, PhD, to learn about the progress in developing a stem cell patch for treating advanced dry age-related macular degeneration. Developed by a team of researchers at USC, the stem cell patch represents a significant advancement in treatment. Dr. Humayun talks about the inspiration behind the patch, how his expertise in both ophthalmology and biomedical engineering has been crucial, and insights gained from a Phase 1/2a study. Dr. Humayun also outlines the upcoming steps for a multisite Phase 2b clinical trial and envisions the potential future role of the stem cell patch in the treatment of geographic atrophy.
    Show more Show less
    25 mins
  • Innovations in Glaucoma Care

    Innovations in Glaucoma Care
    Jun 24 2024
    This podcast features engaging commentary from experts in the clinical management of glaucoma. These experts share information about traditional and newer therapies for glaucoma, including topical drops, sustained drug delivery options, and minimally invasive glaucoma surgery. They discuss safety and efficacy data with an emphasis on appropriate patient selection, as well as key take-home points and practice pearls. Chair: Inas Aboobakar, MD Physician and Surgeon Massachusetts Eye and Ear Instructor in Ophthalmology Harvard Medical School Boston, MA Faculty: Janelle Davison, OD Owner and CEO Brilliant Eyes Vision Center Owner and Clinical Director Premier Dry Eye Spa & Cosmetic Eyecare Marietta, GA Eydie G. Miller-Ellis, MD Professor of Clinical Ophthalmology Perelman School of Medicine at the University of Pennsylvania Director, Glaucoma Service Vice Chair for Faculty Affairs Scheie Eye Institute Perelman Philadelphia, PA
    Show more Show less
    24 mins
  • Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

    Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches
    Jun 20 2024
    The role of calendars may be growing more important when managing patients with nAMD and DME. How many weeks can patients go between injections with newer anti-VEGF agents versus older options? How short of an injection interval can patients tolerate before it becomes too much of a burden? In this podcast, Murtaza Adam, MD; Laxmi Devisetty, MD, Hong-Uyen Hua, MD; and Sherrol Reynolds, OD; share insights into determining appropriate treatment regimens with these therapies and supporting patient adherence.
    Show more Show less
    19 mins
  • S2 Ep38: Claris Bio's journey toward treating neurotrophic keratitis

    S2 Ep38: Claris Bio's journey toward treating neurotrophic keratitis
    Apr 25 2024
    Claris CEO, Clarke Atwell, gives an update on the company and their path toward developing treatment for neurotrophic keratitis
    Show more Show less
    6 mins
  • From Idea to Impact — Navigating Ophthalmic Innovation

    From Idea to Impact — Navigating Ophthalmic Innovation
    Mar 29 2024
    Tune in to the first of a new series of Ophthalmology Times EyePod podcasts focusing on innovation in ophthalmology. Throughout this series, we'll be hearing insights from various stakeholders including those in clinical practice, academia, and industry. The overarching message in this podcast is intended to be informational and not promotional. Today, our host Ehsan Sadri, MD, will be in conversation with Jeffry Weinhuff, who is managing partner of Visionary Ventures. And just a quick note: the thoughts and opinions expressed are those of the speakers and do not necessarily represent the opinions of this publication.
    Show more Show less
    14 mins